FR2881746B1 - Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications - Google Patents

Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications

Info

Publication number
FR2881746B1
FR2881746B1 FR0501198A FR0501198A FR2881746B1 FR 2881746 B1 FR2881746 B1 FR 2881746B1 FR 0501198 A FR0501198 A FR 0501198A FR 0501198 A FR0501198 A FR 0501198A FR 2881746 B1 FR2881746 B1 FR 2881746B1
Authority
FR
France
Prior art keywords
individuals
majority
recognized
tyte
epstein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0501198A
Other languages
English (en)
French (fr)
Other versions
FR2881746A1 (fr
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Lille 2 Droit et Santé
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Centre National de la Recherche Scientifique
Commissariat a lEnergie Atomique CEA
Université Lille 2 Droit et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0501198A priority Critical patent/FR2881746B1/fr
Application filed by Centre National de la Recherche Scientifique, Commissariat a lEnergie Atomique CEA, Université Lille 2 Droit et Santé filed Critical Centre National de la Recherche Scientifique
Priority to PCT/FR2006/000229 priority patent/WO2006082313A2/fr
Priority to EP06709221A priority patent/EP1861418B1/fr
Priority to CA2596929A priority patent/CA2596929C/fr
Priority to US11/883,814 priority patent/US20090130134A1/en
Priority to JP2007553650A priority patent/JP4972562B2/ja
Priority to DE602006011859T priority patent/DE602006011859D1/de
Priority to AT06709221T priority patent/ATE455791T1/de
Publication of FR2881746A1 publication Critical patent/FR2881746A1/fr
Application granted granted Critical
Publication of FR2881746B1 publication Critical patent/FR2881746B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0501198A 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications Expired - Fee Related FR2881746B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
EP06709221A EP1861418B1 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
CA2596929A CA2596929C (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
US11/883,814 US20090130134A1 (en) 2005-02-07 2006-02-02 T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications
JP2007553650A JP4972562B2 (ja) 2005-02-07 2006-02-02 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用
DE602006011859T DE602006011859D1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
AT06709221T ATE455791T1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications

Publications (2)

Publication Number Publication Date
FR2881746A1 FR2881746A1 (fr) 2006-08-11
FR2881746B1 true FR2881746B1 (fr) 2007-04-13

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0501198A Expired - Fee Related FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications

Country Status (8)

Country Link
US (1) US20090130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP1861418B1 (cg-RX-API-DMAC10.html)
JP (1) JP4972562B2 (cg-RX-API-DMAC10.html)
AT (1) ATE455791T1 (cg-RX-API-DMAC10.html)
CA (1) CA2596929C (cg-RX-API-DMAC10.html)
DE (1) DE602006011859D1 (cg-RX-API-DMAC10.html)
FR (1) FR2881746B1 (cg-RX-API-DMAC10.html)
WO (1) WO2006082313A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
KR20200101394A (ko) 2017-12-20 2020-08-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 엡스타인-바 바이러스 항원 구축물
CA3124457A1 (en) * 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
TWI853940B (zh) 2019-05-31 2024-09-01 美商維拉克塔股份有限公司 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
IL295241B1 (en) * 2020-02-10 2026-06-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific T-cell and CD4 cell transfusions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
AU2003246485A1 (en) * 2002-07-16 2004-02-02 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
US20090130134A1 (en) 2009-05-21
JP2008529486A (ja) 2008-08-07
JP4972562B2 (ja) 2012-07-11
DE602006011859D1 (de) 2010-03-11
WO2006082313A2 (fr) 2006-08-10
WO2006082313A3 (fr) 2007-01-11
FR2881746A1 (fr) 2006-08-11
EP1861418A2 (fr) 2007-12-05
ATE455791T1 (de) 2010-02-15
CA2596929A1 (fr) 2006-08-10
EP1861418B1 (fr) 2010-01-20
CA2596929C (fr) 2015-12-29

Similar Documents

Publication Publication Date Title
WO2006082313A3 (fr) Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
IN2012DN01328A (cg-RX-API-DMAC10.html)
EA201000424A1 (ru) Антитела к il-23
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
WO2016201124A3 (en) T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA92505C2 (ru) Композиции на основе антитела против cd3
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2010010467A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
EA201391011A1 (ru) Мономерные и мультимерные иммуногенные пептиды
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
DK1476468T3 (da) Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MX356745B (es) Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20171031